Zobrazeno 1 - 10
of 203
pro vyhledávání: '"PDAC, pancreatic ductal adenocarcinoma"'
Autor:
Song Han, Gerik W. Tushoski-Alemán, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Zhiguang Huo, Jonathan Licht, Thomas J. George, Carmen Allegra, Jose G. Trevino, Steven J. Hughes
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 59, Iss , Pp 101070- (2025)
Oncogenic KRAS signaling plays a critical role in pancreatic ductal adenocarcinoma (PDAC) biology. Recent studies indicate that the combination of MEK and BCL-xL inhibition is synthetically lethal and holds promise for some types of solid cancers, ho
Externí odkaz:
https://doaj.org/article/191df517e9ab4a0b927c1c49c80b247d
Autor:
Chiara Musiu, Francesca Lupo, Antonio Agostini, Gabriella Lionetto, Michele Bevere, Salvatore Paiella, Carmine Carbone, Vincenzo Corbo, Stefano Ugel, Francesco De Sanctis
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Despite the efforts, pancreatic ductal adenocarcinoma (PDAC) is still highly lethal. Therapeutic challenges reside in late diagnosis and establishment of peculiar tumor microenvironment (TME) supporting tumor outgrowth. This stromal landscape is high
Externí odkaz:
https://doaj.org/article/45ea383fc8e649cc854103c3a4f8f1fd
Publikováno v:
Cells, Vol 13, Iss 7, p 602 (2024)
Pancreatic cancer is a highly lethal disease with a 5-year survival rate of around 11–12%. Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The main reason is that when it becomes symptomatic, IT IS the tumor
Externí odkaz:
https://doaj.org/article/a6d4912a31cb402f9284b74190c3f69c
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Pancreatic cancer is a highly malignant tumor known for its extremely low survival rate. The combination of genetic disorders within pancreatic cells and the tumor microenvironment contributes to the emergence and progression of this devastating dise
Externí odkaz:
https://doaj.org/article/a56d3511b9674dcdbab527e218626cc6
Autor:
Roisin McMorrow, Giorgia Zambito, Alex Nigg, Karishma Lila, Thierry P. P. van den Bosch, Clemens W. G. M. Lowik, Laura Mezzanotte
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe location of T-cells during tumor progression and treatment provides crucial information in predicting the response in vivo.MethodsHere, we investigated, using our bioluminescent, dual color, T-cell reporter mouse, termed TbiLuc, T-cel
Externí odkaz:
https://doaj.org/article/0f75ebfaf13b4331997f2b66d1beefdf
Autor:
Jan E. Strøbech, Pietro Giuriatti, Rikke Stagaard, Paulo De Sepulveda, Sebastian R. Nielsen, Janine T. Erler
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Patients with pancreatic ductal adenocarcinoma (PDAC) have a dismal 5-year survival rate of less than 10%, predominantly due to delayed diagnosis and a lack of effective treatment options. In the PDAC tumor microenvironment (TME), neutrophils are amo
Externí odkaz:
https://doaj.org/article/52604e17191a4993b5ac038c3904f7b0
Autor:
Jens von den Driesch, Jana Flöttmann, Friedrich Prall, Christina S. Mullins, Michael Linnebacher, Florian Bürtin
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionMedullary pancreatic carcinoma (MPC) is a rare subtype of pancreatic ductal adenocarcinoma. MPCs represent less than 1% of all pancreatic cancers, and, with only 26 cases in the literature, knowledge regarding drug response and treatment
Externí odkaz:
https://doaj.org/article/b6fd84eef22e4da4a31b7a57d46101fa
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Dimitrios Troumpoukis, Adriana Papadimitropoulou, Chrysanthi Charalampous, Paraskevi Kogionou, Kostas Palamaris, Panagiotis Sarantis, Ioannis Serafimidis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Pancreatic cancer is currently the seventh leading cause of cancer-related deaths worldwide, with the estimated death toll approaching half a million annually. Pancreatic ductal adenocarcinoma (PDAC) is the most common (>90% of cases) and most aggres
Externí odkaz:
https://doaj.org/article/31e8652f187e4638a471c5068568bcc6
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
Externí odkaz:
https://doaj.org/article/194e48fd3cbb4d6894f61db1ab7af281